1 / 31

Nonprescription AC Meeting March 23, 2005

THE QUEST FOR CLINICAL BENEFIT. Steven Osborne, M.D. Medical Officer Division of Over-The-Counter Drug Products. Nonprescription AC Meeting March 23, 2005. Key Issues. Do Clinical Trials Assessing Infection Rates Provide Definitive Evidence Of Clinical Benefit?. Key Issues.

dalia
Download Presentation

Nonprescription AC Meeting March 23, 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. THE QUEST FOR CLINICAL BENEFIT Steven Osborne, M.D. Medical Officer Division of Over-The-Counter Drug Products Nonprescription AC Meeting March 23, 2005

  2. Key Issues • Do Clinical Trials Assessing Infection Rates Provide Definitive Evidence Of Clinical Benefit?

  3. Key Issues • Does the Clinical Evidence Link Surrogate Endpoints With Clinical Benefit?

  4. Monograph Antiseptics • Alcohols (ETOH and IPA) • Purell Handrub • Chlorhexidine (CHG) 2% and 4% Aqueous • Hibiclens and Hibiprep • Iodine or Iodophors (PI) • Tincture of iodine and povidone-iodine (Betadine) • Triclosan • Gojo Antimicrobial Lotion Soap

  5. Monograph Antiseptics • Quaternary Ammonium Compounds • Benzalkonium chloride (Zephiran) • Phenol Derivatives • Carbolic acid • Chloroxylenol (PCMX) • Triclocarban • Safeguard soap

  6. Antiseptic Antimicrobial Spectrum (CDC 2002) Group Gram PositiveGram NegativeSpeed of Action Alcohols +++ +++ Fast Chlorhexidine +++ ++ Intermediate Iodine Compounds +++ +++ Intermediate Iodophors +++ +++ Intermediate Phenol Derivatives +++ + Intermediate Triclosan +++ ++ Intermediate Quaternary AC + ++ Slow +++ excellent, ++ good, but does not include entire bacterial spectrum, + fair

  7. Citizen Petition And Comment • Industry Coalition--Soap and Detergent Association (SDA) and Cosmetic, Toiletry, and Fragrance Association (CTFA): Citizen Petition and Comment to the TFM • Submitted references • Requested FDA lower efficacy standards

  8. Healthcare Procedures • Invasive Procedures: • Surgery • Catheters, IVs • Non-Invasive procedures • Reduce nosocomial infections with handwash • Reduce respiratory and GI illness with handwash

  9. Antiseptics References • Industry Coalition: Citizen Petition and Comment to the TFM: • 155 Articles and Abstracts • 58% HW, 26% PP, 16% SS • Weight of evidence of clinical benefit not persuasive for changing current efficacy criteria • No link between surrogate endpoints and infection rates

  10. Summary Of Study Limitations • Surrogate endpoints not correlated with clinical outcome • Not randomized • No placebo control • Retrospective • Multiple confounders • Inadequately powered • No statistics • Lack of standardization of product use • Irregular patterns of data collection • Failure to address a TFM indication

  11. Study Examples • Maki et al. 1991 (catheter infections) • Luby et al. 2002 (impetigo)

  12. Maki et al 1991 • Randomized study in 668 subjects with IV catheters • all catheters CV or arterial • 2% CHG, 10% PI, 70% IPA • then every other day. No other agents applied

  13. Maki et al 1991 • Endpoints: • Local infection rate (>15 CFUs) • 2.3% for CHG, vs 7.1% (alcohol) and 9.1% (PI), P=0.02 • Bacteremia • 10 total • CHG (1), alcohol (3), PI (6), P=0.18

  14. Maki et al 1991 • No correlation between reduction in bacteria with infection rates • Application of antimicrobial post- catheter insertion limits ability to relate to monograph application

  15. Luby et al 2002 • Double blind, randomized study of antibacterial soap in 241 households in Karachi, Pakistan • Triclocarban soap, bland soap, standard practice group • Primary outcome was incidence of impetigo

  16. Luby et al 2002 • Triclocarban soap 43% less impetigo than standard practice (P=0.02) • Triclocarban 23% less impetigo than than bland soap (P=0.28) • Bland soap 24% less impetigo than standard practice (P=0.21) • Needed 70% increase in sample size

  17. SURGICAL SCRUBS • Surgical hand scrubs • 300 articles screened for clinical benefit • None conclusively linked reduction in bacteria with reduction in infection rates

  18. Study Examples • Bryce et al 2001 • 70% IPA leave-on • in-use hospital evaluation • 70 scrubs by surgeons • 15 ml product used over 3 min • Endpoint: post-op bacterial counts • IPA agent comparable to 4% CHG and 7.5% PI in reducing bacteria • No infection rates studied

  19. Study Examples • Parienti et al. 2002 • Hand-rubbing with alcoholic leave-on solution and 30-day surgical site infection (SSI) rate • Randomized, crossover equivalence trial (75% alcohol, 4% PI, 4% CHG) • 6 surgical services, 4287 pts

  20. Parienti et al. 2002 • Alcohol hand-rub, PI and CHG as hand-scrub • SSI 2.44% alcohol vs. 2.48% with PI+CHG • Scrub time compliance better with alcohol rub (313 sec vs 287 sec, P=0.01) • SSI micro not provided • Surgeon not blinded (reported SSI)

  21. HANDWASH Literature Review • Literature review of healthcare personnel Handwashes 1994-2004 • 222 studies reviewed for clinical benefit or efficacy • None showed a definitive link between bacterial reduction and reduction in infection rates

  22. HANDWASH References • Swoboda et al. 2004, 3-Phase, 15 month evaluation incorporating an electronic monitor (monitor, voice-prompt, monitor) • Compliance improved by 35%, 41% in Phase 2 and 3 • MRSA or VRE colonization rates 19%, 9%, 11%

  23. Patient PREOP Literature Review • 400 articles screened • Searched for bacterial log reduction data post-scrub compared with pre-scrub, then ….. • Searched for SSI rate in same reference

  24. Patient PREOP Literature Review • Majority of studies performed in animals • None of the studies found link between colony forming units (CFU) of bacteria and SSIs

  25. Patient PREOP Literature Review • Secondary topic: Is there a minimum number of bacteria in a wound that predisposes to infection? • 100,000 bacteria (105) • May vary with type of bacteria

  26. Patient PREOP Literature Review • 100,000 bacteria “threshold” for infection • Kass 1957: • 2000 patients with pyelonephritis had >100,000 • 100% of symptomatic patients with UTI had >100,000 • Krizek et al. 1967 • 94% graft success when pre-graft bacteria <100,000/ gram tissue

  27. Study Literature • Cronquist et al. 2001 • 609 neurosurgery patients • Craniotomy • Ventriculo-Peritoneal (VP) shunt • Pre-scrub and post-scrub bacterial counts from head, back

  28. Cronquist et al. 2001 • Bacterial counts (log10):

  29. Study Literature • Cronquist et al. 2001 • 20 SSIs • 19 from craniotomies • Staph species, P. acnes • No correlation between pre-scrub or post scrub counts and SSIs

  30. Key Issues • Do Clinical Trials Assessing Infection Rates Provide Definitive Evidence Of Clinical Benefit?

  31. Key Issues • Does the Clinical Evidence Link Surrogate Endpoints With Clinical Benefit?

More Related